# The Cooper Companies (COO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/COO
## Company Profile
- Ticker: COO
- Exchange: NYSE
- Sector: MedTech
- Location: United States
- Tags: MedTech, Women's Health
## Stock Data
- Close: 76.73 USD
- Market cap: 11607355537.02 USD
- Last updated: 2026-08-12
## Business Overview
### Global Medical Device Company
CooperCompanies is a global medical device company operating through CooperVision and CooperSurgical. Headquartered in San Ramon, California, it employs more than 15,000 people, sells products in over 130 countries, and reaches more than 50 million people annually.
### CooperVision
CooperVision is a major participant in the contact lens market, providing products for routine vision correction and broader eye-health needs. Growth is supported by global myopia-management demand, contact-lens adoption, and product innovation.
### CooperSurgical
CooperSurgical focuses on fertility and women’s health, including assisted reproduction, maternity care, and related medical services. The company has resolved most claims associated with the 2023 voluntary recall of embryo culture media as it continues evaluating strategic options for the business.
### Global Scale and Portfolio Mix
The combination of vision care and women’s health gives CooperCompanies exposure to both recurring consumer demand and procedure-driven clinical markets. Its international distribution footprint supports product sales across more than 130 countries.
## Why The Stock Is Moving

As of Aug 12, 2026, COO was little changed and closed at $76.73. No new same-company headline was identified in the current news window.

## Future Catalysts

- CooperCompanies’ watchlist is contact-lens growth, myopia-management adoption, and continued execution in the fertility and vision franchises. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.

## Recent News
- 2026-07-30 20:15 EST — [CooperCompanies Announces Release Date for Third Quarter 2026](https://biopharmsignal.com/news/COO/coopercompanies-announces-release-date-for-third-quarter-2026-92c94495) — Source: The Cooper Companies
- 2026-06-30 20:15 EST — [CooperCompanies Releases 2025 Corporate Sustainability Report with Scope 3 Emissions Disclosure](https://biopharmsignal.com/news/COO/coopercompanies-releases-2025-corporate-sustainability-report-with-scope-3-emiss-7902aa71) — Source: The Cooper Companies
- 2026-06-04 20:15 EST — [CooperCompanies Announces Second Quarter 2026 Results](https://biopharmsignal.com/news/COO/coopercompanies-announces-second-quarter-2026-results-b3a604de) — Source: The Cooper Companies
- 2026-05-04 20:15 EST — [CooperCompanies Appoints Paul Keel to its Board of Directors](https://biopharmsignal.com/news/COO/coopercompanies-appoints-paul-keel-to-its-board-of-directors-f12e0190) — Source: The Cooper Companies
- 2026-04-30 20:15 EST — [CooperCompanies Announces Release Date for Second Quarter 2026](https://biopharmsignal.com/news/COO/coopercompanies-announces-release-date-for-second-quarter-2026-d53e901c) — Source: The Cooper Companies